

**South East London Area Prescribing Committee
Formulary recommendation**

Reference	029
Intervention:	SURGIFLO[®] Haemostatic matrix kit for the treatment of bleeding in neurosurgical procedures where traditional methods of haemostasis are not effective (Surgiflo [™] Haemostatic Matrix Kit is a medical device with an ancillary medicinal substance [human thrombin] within the device)
Date of Decision	March 2015
Date of Issue:	April 2015
Recommendation:	RED – suitable for usage and supply in hospital setting only
Further Information	<ul style="list-style-type: none"> • SURGIFLO is indicated for epilesional use in surgical procedures (except ophthalmic) for haemostasis, when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical. • A viscous haemostatic product is usually required for neurosurgery, particularly in endoscopic transnasal procedures. FLOSEAL Haemstatic matrix is currently used as the viscous product though there are potential advantages to SURGIFLO product: <ul style="list-style-type: none"> - When preparing for use the viscosity of SURGIFLO can be varied according to requirements. - SURGIFLO has a malleable nozzle allowing improved application to the areas required - SURGIFLO can be prepared in a significantly faster time (81 vs. 168 seconds) - SURGIFLO is available in a larger size (8ml compared to 5ml) • The gelatine in SURGIFLO is of porcine origin whereas the gelatine in FLOSEAL is of bovine origin. Where appropriate this should be highlighted to patients prior to surgery and cultural issues considered when determining which product is chosen during the procedure
Shared Care/ Transfer of care required:	N/A
Cost Impact for agreed patient group	SURGIFLO is £216 per pack which is £24.60 more expensive than FLOSEAL, however due to the larger volume there is less likelihood of needing an additional packs, therefore this is anticipated to be cost neutral.
Usage Monitoring & Impact Assessment	<p>Acute Trusts:</p> <ul style="list-style-type: none"> • Specialist neurosurgery to rationalise use of the haemostatic sealants within a therapy guideline to ensure clarity on which agent is used when. • To audit usage as required. <p>CCGs:</p> <ul style="list-style-type: none"> • Monitor monthly high cost drugs data submitted by Trusts via South East CSU

Evidence reviewed	References (extracted from evidence evaluation)
	<ol style="list-style-type: none"> 1. BA Woodworth et al.2009 A gelatin-thrombin matrix for hemostasis after endoscopic sinus surgery <i>American Journal of Otolaryngology-Head and Neck Medicine and Surgery</i> 30 (2009) 49-53 2. Gazzeri et al 2013 The safety and biocompatibility of gelatin haemostatic matrix (floseal and surgiflo) in neurosurgical procedures <i>Surgical Technology International</i> 2013; Sep1;XXII. pii:sti 22/23

NOTES:

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS**